Semafull 4 mg/3 mL (Semaglutide Injection)

Semafull 4 mg/3 mL (1.34 mg/mL) is designed for patients who have completed the initial GLP-1 receptor agonist titration phase and require a higher maintenance dose for continued treatment. It delivers a more consistent and sustained therapeutic effect, supporting improved glycemic control and enhanced weight loss outcomes.

As a once-weekly subcutaneous injection, Semafull helps regulate blood glucose levels, suppress appetite, and reduce caloric intake. The higher-dose formulation is particularly suitable for ongoing therapy, providing stronger appetite control and long-term metabolic benefits

Recommended Dose (Weekly Injection):

1. Maintenance dose typically ranges from 0.5 mg to 1 mg once weekly
2. Dose may be increased up to 2 mg once weekly depending on individual response and clinical guidance

Administration Guidelines:

• Administer via subcutaneous injection (abdomen, thigh, or upper arm)
• Use on the same day each week for consistency
• Rotate injection sites to minimize irritation
• Can be taken with or without food
• Dose adjustments should be made under medical supervision

Note:
The 4 mg/3 mL strength refers to the total amount of semaglutide in the pen/vial, and each unit can provide multiple doses depending on the prescribed weekly regimen.

Semaglutide Side Effects：

Semaglutide may cause a range of side effects, particularly during dose escalation. Most are mild to moderate and tend to improve as the body adapts to treatment.

Common Side Effects:

• Nausea
• Vomiting
• Constipation
• Diarrhea
• Decreased appetite
• Mild abdominal discomfort

Serious Side Effects:

• Pancreatitis: severe abdominal pain that may radiate to the back
• Hypoglycemia: especially when combined with insulin or sulfonylureas
• Gallbladder disease: including gallstones or inflammation
• Potential thyroid tumors: observed in animal studies

Patients should seek immediate medical attention if they experience severe or persistent symptoms.